ANGIOTENSIN RECEPTOR BLOCKERS AND HCTZ COMBINATION DRUGS

Course overview

SYSTEMIC HYPERTENSION IS A CONDITION THAT POSES A SIGNIFICANT RISK OF COMPLICATIONS FOR PATIENTS WITH CARDIOVASCULAR DISEASE AND CONTRIBUTES SIGNIFICANTLY TO ALL-CAUSE MORTALITY WORLDWIDE. HYPERTENSION IS A PREVENTABLE AND MODIFIABLE RISK FACTOR, AND CONTROLLING BLOOD PRESSURE OFTEN REQUIRES 2 OR MORE ANTIHYPERTENSIVE AGENTS. COMBINING ANGIOTENSIN RECEPTOR BLOCKERS (ARBS) AND HYDROCHLOROTHIAZIDE (HCTZ) EFFECTIVELY CONTROLS BLOOD PRESSURE DUE TO SYNERGISTIC ACTION. WIDESPREAD UNCONTROLLED HYPERTENSION DUE TO POOR MEDICATION ADHERENCE LED TO THE DEVELOPMENT OF SINGLE-PILL COMBINATION MEDICATIONS TO IMPROVE COMPLIANCE. THIS ACTIVITY DISCUSSES THE INDICATIONS, MECHANISMS OF ACTION, ADVERSE EFFECTS, CONTRAINDICATIONS, AND DRUG INTERACTIONS OF COMBINATION ARB-HCTZ THERAPY. UNDERSTANDING EFFECTIVE MANAGEMENT PRACTICES IS CRUCIAL FOR INTERPROFESSIONAL TEAMS PROVIDING CARE TO PATIENTS WITH HYPERTENSION, HELPING MORE PATIENTS ACHIEVE BLOOD PRESSURE TARGETS AND IMPROVED OUTCOMES.